25S rDNA genotype and antifungal susceptibility of clinical Candida albicans in Ouagadougou (Burkina Faso)

Med Mycol. 2018 Oct 1;56(7):907-910. doi: 10.1093/mmy/myx127.

Abstract

The present investigation aimed to assess the prevalence of genotypes of C. albicans in Ouagadougou and to analyze the relationship between the genetic diversity and antifungal susceptibility. Ninety-six clinical strains are included. They were diagnosed as C. albicans using germ tube test, chlamydospore formation, and Api-Candida test. Genotyping was performed using PCR targeting 25S rDNA. Antifungal susceptibilities were tested based on the disk diffusion method. The genotypes A (85.4%) was predominant followed by genotypes B (10.4%) and C (4.2%). The highest resistance rate with genotype A was obtained with fluconazole (74.4%). A resistance to amphotericin B was observed with genotypes A (29.3%) and B (30%).

MeSH terms

  • Antifungal Agents / pharmacology*
  • Burkina Faso
  • Candida albicans / drug effects*
  • Candida albicans / genetics
  • Candida albicans / growth & development
  • Candida albicans / isolation & purification
  • Candidiasis / microbiology*
  • DNA, Ribosomal / genetics*
  • Disk Diffusion Antimicrobial Tests
  • Drug Resistance, Fungal*
  • Genetic Variation
  • Genotype*
  • Genotyping Techniques
  • Humans
  • Polymerase Chain Reaction
  • Prevalence
  • RNA, Ribosomal / genetics*
  • Virulence

Substances

  • Antifungal Agents
  • DNA, Ribosomal
  • RNA, Ribosomal
  • RNA, ribosomal, 25S